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Montreal Heart Institute, Montreal, QC, Canada
This Article is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Dose-Response: An
International Journal by an authorized editor of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.
Recommended Citation
Gendron, Marie-Eve; Thorin-Trescases, Nathalie; Mamarbachi, Aida M; Villeneuve, Louis; Théorêt, Jean-François; Mehri, Yahye; and
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TIME-DEPENDENT BENEFICIAL EFFECT OF CHRONIC POLYPHENOL TREAT-
MENT WITH CATECHIN ON ENDOTHELIAL DYSFUNCTION IN AGING MICE
Marie-Eve Gendron1,4, Nathalie Thorin-Trescases4, Aida M, Mamarbachi4, Louis
Villeneuve4, Jean-François Théorêt4, Yahye Mehri2,4 and Eric Thorin3,4 
1Department of Physiology; 2Department of Medicine; 3Department of Surgery,
Faculty of Medicine, University of Montreal; 4Montreal Heart Institute, Montreal,
QC, Canada.
 A controlled redox environment is essential for vascular cell maturation and function.
During aging, an imbalance occurs, leading to endothelial dysfunction. We hypothesized
that, according to the concept of hormesis, exposure to physiologic oxidative stress dur-
ing the maturation phase of the endothelium will activate protective pathways involved in
stress resistance. C57Bl/6 mice were treated with the polyphenol catechin for the last 3
(post-maturation) or 9 months prior study at 12 months of age. Endothelial dysfunction,
assessed by acetylcholine-induced dilations of isolated renal arteries, was present at 12
months (P<0.05). Only the 3-month treatment with catechin fully prevented the decline
in efficacy and sensitivity to acetylcholine (P<0.05). Splenocytes adhesion to the native
endothelium, expression of CD18 and shedding of CD62L and PSGL-1 augmented in 12
months old mice (P<0.05): only 3-month catechin fully normalized adhesion and pre-
vented the expression of adhesion molecules on splenocytes (P<0.05). Aging was associat-
ed with vascular gene alterations, which were prevented by 3-month catechin treatment
(P<0.05). In contrast, 9-month catechin further increased COX-2, p22phox and reduced
MnSOD (P<0.05). In conclusion, we demonstrate a pivotal role of cellular redox equilibri-
um: exposure to physiologic oxidative stress during the maturation phase of the endothe-
lium is essential for its function.
Key words: mouse arteries, endothelial dysfunction, adhesion, oxidative stress, hormesis.
INTRODUCTION
Many cellular processes such as metabolism, proliferation, growth
and inflammatory host defense involve oxidation/reduction reactions
(Droge, 2002; Holliday, 2006). To function properly, the cell needs there-
fore to monitor and regulate tightly its redox environment (Gendron and
Thorin, 2007; Szocs et al., 2002). Few data underscore the role of the redox
poise on the cellular maturation and/or differentiation (Focardi et al.,
2007). In particular, the role of the redox environment as a regulator of
vascular endothelial cell function and maturation is not well defined.
Vascular aging leads to an unbalanced redox environment towards oxi-
dation that is associated with impaired endothelium-dependent dilation,
Address correspondence to Eric Thorin, Institut de Cardiologie de Montréal, Centre de
recherche, 5000 rue Bélanger, Montréal, QC, H1T 1C8, Canada; Tel: (514) 376-3330; Fax:
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enhanced endothelial activation and inflammation (Csiszar et al., 2002;
Donato et al., 2007). The mechanisms by which oxidative stress is respon-
sible for endothelial cell dysfunction may include DNA, protein and lipid
damages, alteration of gene expression and decreased NO availability
(Kregel and Zhang, 2007; Rattan, 2008b). There is therefore a strong
rationale for using antioxidants in preventing age-related cardiovascular
decline (Baur and Sinclair, 2006). Antioxidant polyphenols, such as cate-
chin, are abundant in fruits, vegetables, green tea and red wine; they
increase the efficacy and/or production of endothelium-derived relaxing
factors (Schini-Kerth et al., 2010; Stoclet et al., 2004), improve the efficacy
of endogenous antioxidants and act as direct free radical scavengers
(Nijveldt et al., 2001; Robak and Gryglewski, 1988). Polyphenols have been
extensively studied regarding their effects on cardiovascular diseases (see
for review (Arts and Hollman, 2005)). These studies have yielded mixed
results, probably due to different experimental settings and conditions.
Although no data are available in the literature, it is possible that if initi-
ated too early in life, an antioxidant treatment may impair proper cell mat-
uration and thus cell function. In accordance with the concept of horme-
sis where mild stress activates different endogenous mechanisms of repair
and maintenance to protect cells against subsequent stresses (Gems and
Partridge, 2008; Rattan, 2008a; Zhang et al., 2008), we hypothesized that
exposure to physiologic oxidative stress during the maturation phase of
the endothelium will activate protective pathways involved in stress resist-
ance. In the present study, the antioxidant properties of the polyphenol
catechin were used in order to indirectly demonstrate a pivotal role of cel-
lular redox equilibrium in vascular cell development, maturation and func-
tion: the impact of catechin antioxidant treatment, initiated before and
after maturation, on endothelial dysfunction and inflammation associated
with aging of C57Bl/6 mice was investigated. Our data demonstrate that
secondary catechin treatment is more effective than the treatment initiat-
ed before maturation at preserving endothelial function and avoiding
inflammation, possibly by conserving the redox equilibrium essential for
the proper maturation of the endothelium. The exposure of the endothe-
lium to physiologic oxidative stress during its maturation phase is likely
beneficial and may determine vascular longevity.
MATERIAL AND METHODS
Experimental groups
All experiments were performed using C57Bl/6 male mice. Mice
were randomly assigned to the following 3 groups: treatment with the
antioxidant polyphenol catechin (30 mg/kg/day; (Drouin et al., 2011;
Gendron et al., 2010)) in the drinking water from 3 to 12 months (CAT
9; primary treatment), from 9 to 12 months (CAT 3; secondary treat-
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ment) or no treatment (control). The dose of catechin was chosen to pro-
vide an appropriate dietary intake of ≈ 0.75 mg/day and per mouse of cat-
echin (Hishikawa et al., 2005; Loke et al. 2010; Miura et al., 2001;
Waddington et al., 2004). Three months old C57Bl/6 mice were used as
young reference mice. Twelve months old C57Bl/6 mice are considered
in the present study as middle-aged mice, since 50 % of mortality occur
around 25 months of age and the maximal life expectancy of C57Bl/6
mice is around 36 months of age (Forster et al., 2003; Wolf et al., 2000).
At the end of the catechin treatment period, renal arteries were harvest-
ed for vascular reactivity studies (Gendron et al., 2010; Gendron and
Thorin, 2007); the aorta was either snap frozen for total RNA extraction
(Gendron and Thorin, 2007) or freshly prepared for the splenocyte adhe-
sion onto the native endothelium (Gendron et al., 2010). All experiments
have been approved by our ethical institutional committee and per-
formed in accordance with the guidelines for animal experimentation of
the Canadian Council on Animal care Protection (CCAP).
Vascular reactivity studies
Experiments were conducted in isolated and pressurized (100 mm
Hg) mouse renal arteries (external diameter ≈ 400 µm) as previously
described (Gendron et al., 2007). Arterial segments were pre-constricted
with phenylephrine (PE; 30 µmol/L) and concentration-response curves
to acetylcholine (ACh; 0.001 µmol/L - 30 µmol/L) were constructed.
Half-maximum effective concentration (EC50) of ACh was measured from
individual concentration-response curves; the pD2 value, the negative log
of the EC50, was obtained. ACh-induced dilations are expressed as a per-
centage of the maximal diameter obtained in a calcium-free solution.
Splenocyte adhesion studies
The number of splenocytes adhering to the native endothelium was
assessed as previously described (Gendron et al., 2010) and expressed per
surface area of the aortic segment (splenocytes/mm2).
Flow cytometry studies
Splenocyte suspensions (5 x 106 cell/ml) were incubated with differ-
ent monoclonal antibodies (CD18-, CD62L- or CD162 (PSGL-1)-phyco-
erythrein-conjugated, from Serotec) or their isotype-matched control
IgGs, as previously described (Gendron et al., 2010). Antibody binding
was determined as the percentage of positive splenocytes or the mean flu-
orescence intensity (MFI) over a fluorescence threshold gated over a
splenocyte population stained with the proper isotype-matched control
IgG (<2% of positive cells). The binding index (% of positive cells x MFI)
was then calculated.
M.-E. Gendron and others
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Quantification of gene expression by Real-Time polymerase chain reaction
(qPCR)
Total RNA was extracted from aorta using an RNeasy mini-kit (Qiagen
Inc). Efficient extraction was possible by performing additional steps of
digestion with proteinase K (Qiagen Inc) and by eliminating DNA with a
treatment with DNase I (Qiagen Inc). The reverse transcriptase reaction
contained 5 ng/µL total RNA (each sample), M-MLV reverse transcrip-
tase (200 U, Invitrogen), anti-sens primer (4 pM, Invitrogen), dNTPs (0.5
mmol/L, MBI Fermentas), and supplied optimal buffers. The reaction
protocol consisted of 3 successive incubation steps: 1) 25°C for 10 min-
utes; 2) 37°C for 50 minutes; and 3) 70°C for 15 minutes.
qPCR was performed as previously (Gendron and Thorin, 2007) with
2 ng of cDNA template containing the appropriate primer concentration;
Sirtuin-1 (100 nM); p22phox (300 nM); MnSOD (300 nM); COX-2 (300
nM); cyclophilin A (300 nM) and SYBR Green PCR master mix
(Stratagene).
Primers for each gene were obtained from distinct exons that
spanned an intron by using the Ensembl genome browser
(http://www.ensembl.org). The sequence specificity of each primer was
verified with the Blast program derived from the National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov). The primers
used were as follows: for mouse Sirtuin-1: forward 5’-GAGCAGGTTGCA
GGAATCCA-3’ and reverse 5’-CCTGATTAAAAATGTCTCCACGAA-3’;
for mouse p22phox: forward 5’-GGCTGCCCTCCACTTCCT-3’ and reverse
5’-CTCCTTGGGTTTAGGCTCAATG-3’; for mouse MnSOD: foward 
5’-GGCCAAGGGAGATGTTACAA-3’ and reverse 5’-GCTTGATAGCCTC
CAGCAAC-3’; for mouse COX-2: forward 5’-GAACATGGACTCACT
CAGTTTGTTG-3’ and reverse 5’-CAAAGATAGCATCTGGACGAGGT-3’;
for mouse cyclophilin A: forward 5’-CCGATGACGAGCCCTTGG-3’ and
reverse 5’-GCCGCCAGTGCCATTATG-3’.
PCR products were purified, sequenced and confirmed to be the
genes of interest.
Statistical Analysis
In every case, n refers to the number of animals used in each proto-
col. Continuous variables are expressed as means ± standard error of the
mean (SEM). ANOVA studies followed by a Scheffé’s F test were per-
formed to compare Emax and pD2 of dose-response curves as well for adhe-
sion and qPCR studies. Unpaired t-tests were performed for flow cytome-
try studies. Differences were considered to be statistically significant for a
P value <0.05.
Hormesis and vascular endothelial function in aging
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RESULTS
Secondary catechin treatment fully prevents age-dependent endothelial
dysfunction.
Vascular sensitivity (pD2: 6.7±0.1 versus 6.3±0.1, 3- versus 12-month
old) and maximal dilation (Emax: 90±5 versus 64±10 %, 3- versus 12-month
old) to ACh were lower (P<0.05) at 12-month old than at 3-month old
(Fig. 1). Both secondary (3 months) and primary (9 months) treatments
with catechin normalized Emax (87±3 versus 86±4 %, CAT-3- versus CAT-9,
P<0.05). Only the secondary treatment, however, normalized (P<0.05)
the vascular sensitivity to ACh comparable to that measured at the age of
3 months (6.6±0.1 versus 6.2±0.1, CAT-3- versus CAT-9, P<0.05).
Secondary catechin treatment fully prevents age-dependent splenocyte
adhesion onto the endothelium
Basal splenocyte adhesion onto the endothelium increased signifi-
cantly in 12-month old mice (207±16 splenocytes/mm2) compared to 3-
month old mice (127±10 splenocytes/mm2, P<0.05) (Fig. 2). To deter-
mine whether the endothelium and/or the splenocytes were dysfunc-
tional, we first performed a crossover study in which the endothelium of
3-month old mice was exposed to splenocytes of 12-month old mice and
vice-versa: in both cases adhesiveness was increased (P<0.05; data not
shown). Catechin prevented (P<0.05) the rise of basal splenocyte adhe-
sion irrespective of the duration of the treatment (Fig. 2). This rise of
splenocyte adhesion with aging and its prevention by catechin was also
observed by confocal microscopy using CD45 and VE-cadherin to visual-
ize splenocytes and endothelial cells, respectively (data not shown).
M.-E. Gendron and others
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FIGURE 1. Secondary catechin treatment fully prevents age-dependent endothelial dysfunction. Dose-response
curves to acetylcholine of renal arteries isolated from 3-month old mice, 12-month old untreated mice and
12-month old mice treated for the last 3 months (CAT 3) or the last 9 months (CAT 9) with catechin.
Data are mean±SEM, n = 7. *: P<0.05 compared to endothelium-dependent dilations observed in 3-month
old mice; φ: P<0.05 compared to endothelium-dependent dilations observed in 12-month old mice. 
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Stimulation of the endothelium with histamine increased significant-
ly adhesion in 3-month old mice from 127±10 to 228±13 splenocyte/mm2,
a level similar to that measured in 12-month old mice in basal conditions,
confirming the activated state of the endothelium (Fig. 2). Histamine,
however, did not further increase splenocyte adhesion at 12 months when
compared to baseline. Only the secondary catechin treatment fully pre-
vented histamine-induced adhesion of the splenocytes to the endotheli-
um (Fig. 2).
Secondary catechin treatment fully prevents age-dependent increase in the
expression of splenocyte cell adhesion molecules
Aging was associated with a significant up-regulation of splenocyte
CD18 expression and shedding of CD62L and PSGL-1 (Fig. 3). Only the
secondary catechin regimen completely prevented these changes (Fig.3).
Hormesis and vascular endothelial function in aging
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FIGURE 2. Secondary catechin treatment fully prevents age-dependent splenocyte adhesion onto the endothelium.
Splenocyte adhesion onto the native endothelium of aortic segments isolated from 3-month old
mice, 12-month old untreated mice and 12-month old mice treated for the last 3 months (+ CAT 3)
or the last 9 months (+ CAT 9) with catechin. Responses were obtained either in basal conditions
(baseline) or following stimulation of the native endothelium with histamine (0.1 µM).
Data are mean±SEM (A) and the corresponding individual data (B) of n = 5-29.
*: P<0.05 compared to 3-month old mice; †: P<0.05 compared to 12-month old mice; ‡: P<0.05 com-
pared to baseline. 
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Secondary catechin treatment prevents age-dependent changes in gene
expression
Expression of SIRT-1 was decreased (P<0.05) in 12-month old when
compared to 3-month old mice (Fig. 4B). In contrast, aging was associat-
ed with a 2-fold increase in COX-2 expression (P<0.05; Fig. 4A) without
any changes in p22phox and MnSOD expression (Fig. 4). The secondary
M.-E. Gendron and others
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FIGURE 3. Secondary catechin treatment fully prevents age-dependent increase in the expression of splenocyte cell
adhesion molecules. Expression of cell adhesion molecules measured by flow cytometry on the surface
of splenocytes isolated from 3-month old mice, 12-month old untreated mice and 12-month old mice
treated for the last 3 months (+ CAT 3) or the last 9 months (+ CAT 9) with catechin.
Individual data and the corresponding mean±SEM, n = 9-18 are illustrated for (A) CD18, (B) CD62L
and (C) PSGL-1. *: P<0.05 compared to 3-month old mice; †: P<0.05 compared to 12-month old mice. 
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catechin treatment prevented the age-dependent rise in COX-2 expres-
sion and the decline in SIRT-1 expression. In contrast, primary treatment
increased by 50 times COX-2 expression, enhanced significantly mRNA
expression of the free radical producing enzyme p22phox, while it
decreased significantly the expression of the free radical inactivating
enzyme MnSOD (Fig. 4). Finally, the expression of the polyphenol-sensi-
tive longevity gene SIRT-1 was 4-fold increased by the primary treatment
with catechin (Fig. 4B).
DISCUSSION
In the present study, we show that the endothelial function is dependent
on a tightly regulated redox environment. We demonstrate that a second-
ary antioxidant treatment (from 9- to 12-month of age) with the polyphe-
nol catechin is more efficient than a primary treatment (from 3- to 12-
month of age) in preventing endothelial dysfunction associated with nor-
mal aging in mice. This is highlighted by a better endothelial dilatory sen-
sitivity to ACh, a reduced adhesion of splenocytes onto the endothelium,
an improved expression profile of splenocytes adhesion molecules, and
finally by the maintenance of a favorable vascular-related gene expres-
Hormesis and vascular endothelial function in aging
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FIGURE 4. Secondary catechin treatment prevents age-dependent changes in gene expression. Gene expression
from total RNA isolated from the aorta of 3-month old mice, 12-month old untreated mice and 12-
month old mice treated for the last 3 months (+ CAT 3) or the last 9 months (+ CAT 9) with catechin.
Gene expression of (A) COX-2, (B) SIRT-1, (C) p22phox and (D) MnSOD was measured by qPCR.
Data are mean±SEM, n = 3-5. *: P<0.05 compared to 3- month old mice; †: P<0.05 compared to 12-
month old mice. 
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sion. Thus, a physiological redox-sensitive maturation process likely occurs
in the endothelium, suggesting that the exposure of the endothelium to
physiologic oxidative stress during its maturation phase is beneficial. This
is in accordance with the concept of hormesis, where exposure to a mild
stress (oxidative stress in this case) promotes protection against further
stress.
In 12-month old mice, we observed that vascular sensitivity and max-
imal dilation to ACh are reduced when compared to 3-month old mice.
This age-dependent decline in the endothelial function is in accordance
with our previous work (Gendron et al., 2007; Krummen et al., 2006) and
the literature (Brandes et al., 2005). The endothelial capacity to limit
leukocyte adhesion is also weakened with aging. Our data show that both
the endothelium and the splenocytes are prone to adhesion at 12 months
of age. The shortest and latest catechin treatment paradigm proved to be
the most efficient at preventing endothelium dysfunction and the
increase in splenocyte/endothelium interactions with aging. This sec-
ondary treatment also prevented the age-dependent increase in CD18
expression and shedding of CD62L and PSGL-1, suggesting a normaliza-
tion of splenocyte function. The primary treatment with catechin neither
fully prevented endothelial dysfunction nor splenocyte adhesion mole-
cule expression. It is well established that the expression of cell adhesion
molecules increases with raised free radical production and is sensitive to
an antioxidant treatment (Chen et al., 2004; Ludwig et al., 2004), but the
duration of such therapy may considerably influence the outcome. Our
data suggest that catechin treatment initiated during the maturation of
the endothelium (from 3 to 9 months of age) could prevent adaptive
pathways responsible for cellular and physiological homeostasis, such as
antioxidant enzymes to maintain an appropriate redox environment
(Zhang et al., 2008). Cellular maintenance processes are necessary to pro-
tect against the molecular damages that cause aging (Gems and
Partridge, 2008), and we propose that an early and long exposure to cat-
echin prevents the normal establishment of these protective processes.
Exposure to oxidative stress during the maturation of the endothelium
likely enables it to more successfully cope with the rise in oxidative stress
associated with aging. This is the concept of hormesis, adapted to the con-
text of aging (Rattan, 2008a; Rattan, 2008b), where the “hormetin”, i.e.
the stress inducing resistance against subsequent stress, is oxidative stress.
The effectiveness of secondary versus primary catechin treatment is
further demonstrated by the expression profile of various genes involved
in the pathways that regulate vascular tone and the redox environment. We
previously reported that aging was associated with a reduction in eNOS
and an augmentation in COX-2 expression (Gendron et al., 2007). The
secondary treatment that fully preserved endothelial function also pre-
vented the rise in COX-2. In contrast, primary treatment with catechin
M.-E. Gendron and others
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drastically increased COX-2 gene expression. Our data therefore suggest
that during the course of maturation, expression of key endothelial play-
ers occurs and is altered by the primary catechin treatment. We propose
that during this phase, the reducing environment created by catechin, as
demonstrated by the decrease in MnSOD expression (Zhang et al., 2002),
is deleterious. This hypothesis is supported by the up-regulation of the
p22phox, a subunit of the NADPH oxidase (Bedard and Krause, 2007)
observed only in the group of mice treated with catechin for 9 months.
Primary catechin treatment induces a rupture in the normal redox envi-
ronment and likely alters the multiple protective and adaptive cellular
pathways responsible for stress resistance.
We demonstrate that chronic exposure to catechin during the matu-
ration period of the mouse increases SIRT-1 gene expression. Although
the increase in SIRT-1 expression had to be expected since it is a marker
of the polyphenol response (Kaeberlein et al., 2005), it is striking that
SIRT-1 expression increases only if the treatment is initiated at 3 months
of age. Absence of impact of the secondary treatment with catechin on
SIRT-1 gene expression does not, however, utterly mean that the polyphe-
nol did not have any impact. It will be important to study the longevity of
mice treated with catechin from the age of 3 months compared to that of
animals treated from the age of 9 months. One should be interested to
see if preserving a seemingly “young” vascular phenotype, as observed
with the secondary treatment, is as effective as increasing SIRT-1 gene
expression in prolonging lifespan. This study would also be informative
considering that resveratrol has been shown to protect mice on a high fat
diet starting at 12 months of age (Baur et al., 2006).
To conclude, our results reveal that the age-dependent changes in
endothelial function were best prevented by a secondary, post-matura-
tion, catechin treatment. This was associated with maintenance of
endothelial dilatory function, a reduced adhesiveness of splenocytes onto
the endothelium, an improved expression profile of both splenocytes and
endothelial cell adhesion molecules, and maintenance of most vascular-
related gene expression tested. This highlights the importance of a tightly
regulated redox environment to provide an adequate development/matu-
ration and function. This essential maturation process likely includes pro-
tective and adaptive cellular pathways responsible for stress resistance,
according to the hormetic concept in aging (Le Bourg and Rattan, 2009):
mild oxidative stress during maturation promotes stress resistance later in
life. Hormesis could contribute to the beneficial effects of the late-cate-
chin regimen, by promoting resistance to endothelial dysfunction associ-
ated with healthy aging.
Hormesis and vascular endothelial function in aging
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